Intermezzo (Zolpidem Tartrate) Sublingual Tablet C-IV: Pk/Pd Profile Supports Middle-of-the-Night Dosing of 1.75 Mg in Women and 3.5 Mg in Men

Trial Profile

Intermezzo (Zolpidem Tartrate) Sublingual Tablet C-IV: Pk/Pd Profile Supports Middle-of-the-Night Dosing of 1.75 Mg in Women and 3.5 Mg in Men

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2013

At a glance

  • Drugs Zolpidem (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Nov 2013 Results published in the Journal of Clinical Pharmacology.
    • 11 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top